Document Detail

Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Examination of the evidence from six hypertension intervention trials.
MedLine Citation:
PMID:  3309458     Owner:  NLM     Status:  MEDLINE    
Over the past 6 years, major hypertension intervention studies in Europe, Australia, and the USA have shown disappointing results in the prevention of coronary heart disease (CHD) in spite of adequate treatment and good compliance. Recently, it has become increasingly clear that hypertensives with or without treatment display higher cholesterol levels than normotensive persons. The present review examines cholesterol levels in six intervention studies, none of which offered dietary or drug therapy for hypercholesterolemic patients. The Oslo study and the British MRC Trial reported very high average cholesterol levels and both showed no protection from CHD through intensive therapy in comparison to control patients. The Australian and the American MRFIT studies produced evidence for reduced coronary mortality among hypertensives with low in contrast to those with high cholesterol levels. The European Working Party showed indirectly that patients with marked reduction in blood pressure and cholesterol had a significantly lower cardiac mortality compared to placebo-treated patients. The IPPPSH study found that increasing cholesterol levels in hypertensives under beta blocker or diuretic therapy increased the risk of myocardial infarction. Failure to reduce cholesterol in hypertensive patients apparently is a major reason for the limited efficacy of antihypertensive treatment in the reduction of CHD.
S Heyden; K A Schneider; G J Fodor
Related Documents :
9015468 - The one-stop coronary cholesterol clinic: a multidisciplinary approach to implementing ...
20675108 - Atherogenic dyslipidemia in patients with established coronary artery disease.
9117138 - Economic issues in coronary heart disease prevention.
15540478 - Hmg-coa reductase inhibitors for lowering elevated levels of c-reactive protein.
17437588 - Value of pacemaker atrial diagnostic data in patients with paroxysmal atrial fibrillati...
1764838 - Safety and efficacy of sonicated albumin microspheres in perfusion and vein graft paten...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Klinische Wochenschrift     Volume:  65     ISSN:  0023-2173     ISO Abbreviation:  Klin. Wochenschr.     Publication Date:  1987 Sep 
Date Detail:
Created Date:  1987-11-17     Completed Date:  1987-11-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985205R     Medline TA:  Klin Wochenschr     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  828-32     Citation Subset:  IM    
Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Cholesterol / blood*
Clinical Trials as Topic
Coronary Disease / blood,  prevention & control*
Hypertension / blood,  drug therapy*
Risk Factors
Reg. No./Substance:
0/Antihypertensive Agents; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adipose tissue development: the role of precursor cells and adipogenic factors. Part II: The regulat...
Next Document:  Methods for the metabolic quantification of regional myocardial ischemia.